Overview
Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
•Develop models for early and effective biomarker testing
•Assess the most recent evidence with selecting and sequencing treatments
•Create appropriate gastric/GEJ cancer treatment plans that implement the latest data and recommendations
•Incorporate multidisciplinary strategies to manage potential gastric/GEJ cancer treatment-related adverse events
Provided by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Oncology
Weill Cornell Medicine
New York, NY
The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL) require that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Manish A. Shah, MD FASCO
Sources of Funding for Research: Bristol Meyers Squibb, Merck & Co., Oncolys BioPharma, Inc.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Chicago Pritzker School of Medicine and ACHL require speakers to disclose that a product is not labeled for the use under discussion.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
